TG THERAPEUTICS, INC. (TGTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 90M 180M 270M Q3 '21: 2M Q4 '21: 2.3M Q1 '22: 2M Q2 '22: 594K Q3 '22: 94K Q4 '22: 80K Q1 '23: 7.8M Q2 '23: 16.1M Q3 '23: 165.8M Q4 '23: 44M Q1 '24: 63.5M Q2 '24: 73.5M Q3 '24: 83.9M Q4 '24: 108.2M Q1 '25: 120.9M Q2 '25: 141.1M Q3 '25: 161.7M Q4 '25: 192.6M Q1 '26: 204.9M Q2 '26: 240.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 70M 140M 210M Q3 '22: 92K Q4 '22: 77K Q1 '23: 6.9M Q2 '23: 14.2M Q3 '23: 162.3M Q4 '23: 36.1M Q1 '24: 58M Q2 '24: 65.2M Q3 '24: 74.5M Q4 '24: 92.8M Q1 '25: 105.3M Q2 '25: 122.2M Q3 '25: 133.6M Q4 '25: 154.4M Q1 '26: 171.4M Q2 '26: 199.1M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-120M -80M -40M 0 40M 80M 120M Q3 '21: -85.1M Q4 '21: -92.9M Q1 '22: -66.9M Q2 '22: -38.9M Q3 '22: -35M Q4 '22: -77.5M Q1 '23: -37M Q2 '23: -44.7M Q3 '23: 114.8M Q4 '23: -12.5M Q1 '24: -9.3M Q2 '24: 8.8M Q3 '24: 12.4M Q4 '24: 29.9M Q1 '25: 8.6M Q2 '25: 34.8M Q3 '25: 29.4M Q4 '25: 50.5M Q1 '26: 34.8M Q2 '26: 21.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-150M 0 150M 300M 450M Q3 '21: -85.6M Q4 '21: -93.3M Q1 '22: -69M Q2 '22: -40.5M Q3 '22: -35.8M Q4 '22: -78.5M Q1 '23: -39.2M Q2 '23: -47.6M Q3 '23: 113.9M Q4 '23: -14.4M Q1 '24: -10.7M Q2 '24: 6.9M Q3 '24: 3.9M Q4 '24: 23.3M Q1 '25: 5.1M Q2 '25: 28.2M Q3 '25: 390.9M Q4 '25: 23M Q1 '26: 19.8M Q2 '26: 7.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 15M 30M 45M Q1 '21: 139K Q3 '22: 2K Q4 '22: 3K Q1 '23: 857K Q2 '23: 1.9M Q3 '23: 3.5M Q4 '23: 7.9M Q1 '24: 5.4M Q2 '24: 8.3M Q3 '24: 9.3M Q4 '24: 15.4M Q1 '25: 15.5M Q2 '25: 18.9M Q3 '25: 28.1M Q4 '25: 38.1M Q1 '26: 33.5M Q2 '26: 41.2M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '21: -67.2M Q4 '21: -86.9M Q1 '22: -68.7M Q2 '22: -49.1M Q3 '22: -34.5M Q4 '22: -23.9M Q1 '23: -59.9M Q2 '23: -42M Q3 '23: 83.7M Q4 '23: -13.2M Q1 '24: -8.2M Q2 '24: 5.5M Q3 '24: -12.2M Q4 '24: -25.6M Q1 '25: -28.7M Q2 '25: 7.4M Q3 '25: -23.2M Q4 '25: 19.7M Q1 '26: -17.9M Q2 '26: 39.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-90M -60M -30M 0 30M 60M 90M Q4 '20: -52.2M Q1 '21: -81.4M Q2 '21: -60.3M Q3 '21: -67.3M Q4 '21: -87M Q1 '22: -68.7M Q2 '22: -49.1M Q3 '22: -34.5M Q4 '22: -23.9M Q4 '23: -13.2M Q1 '24: -8.2M Q2 '24: 5.5M Q3 '24: -12.2M Q4 '24: -25.7M Q1 '25: -28.7M Q2 '25: 7.4M Q3 '25: -23.2M Q4 '25: 19.6M Q1 '26: -17.9M Q2 '26: 39M Q1 '21 Q4 '21 Q3 '22 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q1 '21: 131.9M Q2 '21: 132.1M Q3 '21: 132.4M Q1 '22: 134.4M Q2 '22: 134.8M Q3 '22: 135.3M Q1 '23: 140.3M Q2 '23: 141.5M Q3 '23: 155.9M Q1 '24: 146.2M Q2 '24: 159.4M Q3 '24: 160.7M Q1 '25: 162.8M Q2 '25: 162.6M Q3 '25: 161M Q1 '26: 160.1M Q2 '26: 157.3M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3.00 -2.00 -1.00 0.00 1.00 2.00 3.00 Q3 '21: -2.65 Q4 '21: -2.63 Q1 '22: -2.45 Q2 '22: -2.16 Q3 '22: -1.77 Q4 '22: -1.64 Q1 '23: -1.41 Q2 '23: -1.45 Q3 '23: -0.46 Q4 '23: 0.09 Q1 '24: 0.30 Q2 '24: 0.68 Q3 '24: -0.03 Q4 '24: 0.14 Q1 '25: 0.24 Q2 '25: 0.37 Q3 '25: 2.78 Q4 '25: 2.78 Q1 '26: 2.87 Q2 '26: 2.75 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.